Description of Business (Details) $ in Thousands	1 Months Ended
	Jun. 30, 2025	Dec. 31, 2025 USD ($) designation	Oct. 18, 2025 patient	Sep. 30, 2025 site patient	Apr. 28, 2025 patient	Dec. 31, 2024 USD ($)
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Cash cash equivalents and restricted cash | $		$ 43,500
Short-term investments | $		$ 47,582				$ 20,821
HEPZATO KIT
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Number of orphan drug designations granted by FDA		6
Clinical trial, number of patients | patient				90	90
Clinical trial, number of sites (more than) | site				20
HEPZATO KIT, Melphalan
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Number of orphan drug designations granted by FDA		5
HEPZATO KIT, Doxorubicin
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Number of orphan drug designations granted by FDA		1
CHEMOSAT
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Product reimbursement period	2 years
Clinical trial, number of patients | patient			76